Crescent Biopharma, Inc. Cash Flow-to-Debt Ratio
Crescent Biopharma, Inc. cash flow-to-debt ratio. Crescent Biopharma, Inc. (CBIO) has a Cash Flow-to-Debt Ratio of -1.00x as of June 2026, meaning its operating cash flow of $-19.46 Million could theoretically repay -1% of its total liabilities ($19.50 Million) in one year. Check how high is Crescent Biopharma, Inc.'s earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Crescent Biopharma, Inc. (2011–2025)
Cash flow-to-debt ratio of Crescent Biopharma, Inc. from 2011 to 2025. Historical debt coverage capacity for Crescent Biopharma, Inc. across 15 annual periods. Check CBIO capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Crescent Biopharma, Inc. Cash Flow-to-Debt Ratio by Year (2011–2025)
Crescent Biopharma, Inc. cash flow-to-debt ratio by year from 2011 to 2025. Year-by-year debt coverage analysis for Crescent Biopharma, Inc.. For the full cash flow conversion analysis, see Crescent Biopharma, Inc. cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.92x | $-71.53 Million | $37.28 Million | ▼ -215.3% |
| 2024 | -0.61x | $-31.10 Million | $51.10 Million | ▲ +88.0% |
| 2023 | -5.05x | $-34.88 Million | $6.90 Million | ▲ +3.4% |
| 2022 | -5.23x | $-46.46 Million | $8.88 Million | ▼ -16.0% |
| 2021 | -4.51x | $-57.49 Million | $12.74 Million | ▼ -68.0% |
| 2020 | -2.69x | $-39.24 Million | $14.61 Million | ▲ +28.9% |
| 2019 | -3.78x | $-51.98 Million | $13.77 Million | ▲ +18.3% |
| 2018 | -4.62x | $-43.33 Million | $9.38 Million | ▼ -37.9% |
| 2017 | -3.35x | $-29.77 Million | $8.88 Million | ▲ +20.1% |
| 2016 | -4.20x | $-29.73 Million | $7.09 Million | ▼ -306.7% |
| 2015 | -1.03x | $-8.24 Million | $7.99 Million | ▼ -55.6% |
| 2014 | -0.66x | $-4.28 Million | $6.46 Million | ▲ +89.9% |
| 2013 | -6.54x | $-15.54 Million | $2.38 Million | ▼ -267.9% |
| 2012 | -1.78x | $-10.47 Million | $5.89 Million | ▼ -362.5% |
| 2011 | 0.68x | $13.85 Million | $20.45 Million | — |